Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumorsMing Yi, Kongming Wu, Dechao Jiao et al.|Journal of Hematology & Oncology|2022Cited by 178
Vγ2 x PD-L1, a Bispecific Antibody Targeting Both the Vγ2 TCR and PD-L1, Improves the Anti-Tumor Response of Vγ2Vδ2 T CellRui Yang, Pengfei Zhou|Frontiers in Immunology|2022Cited by 10